Bausch & Lomb (STU:S2L) Additional Paid-In Capital : €7,814 Mil(As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Additional Paid-In Capital?

Bausch & Lomb's quarterly additional paid-in capital increased from Sep. 2024 (€7,573 Mil) to Dec. 2024 (€8,050 Mil) but then stayed the same from Dec. 2024 (€8,050 Mil) to Mar. 2025 (€7,814 Mil).

Bausch & Lomb's annual additional paid-in capital declined from Dec. 2022 (€7,821 Mil) to Dec. 2023 (€7,656 Mil) but then increased from Dec. 2023 (€7,656 Mil) to Dec. 2024 (€8,050 Mil).

Bausch & Lomb Additional Paid-In Capital Historical Data

The historical data trend for Bausch & Lomb's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Additional Paid-In Capital Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

7,821.04

7,656.03

8,049.70

Bausch & Lomb Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial														7,693.96	7,786.88	7,572.91	8,049.70	7,814.40

Bausch & Lomb Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Bausch & Lomb Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (STU:S2L) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BLCO:USA BLCO:Canada

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Bausch & Lomb Headlines

No Headlines